Valneva SE
1,9100
23-декабря-24 09:32:26
15 мин. задержка
Акции
-0,0190
-0,98%
Сегодняшний диапазон
1,8960 - 1,9640
ISIN
FR0004056851
Источник
Cboe
- Котировки
- Графики
Новости
- Статистика
-
VALNEVA - Declaration of shares and voting rights: July 31, 2024
06 авг 2024 02:30:00 Источник Nasdaq GlobeNewswire
-
01 авг 2024 01:00:00 Источник Nasdaq GlobeNewswire
-
22 июл 2024 01:00:00 Источник Nasdaq GlobeNewswire
-
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
17 июл 2024 16:00:00 Источник Nasdaq GlobeNewswire
-
Declaration of shares and voting rights - Valneva SE - June 30, 2024
04 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
-
01 июл 2024 01:00:00 Источник Nasdaq GlobeNewswire
-
26 июн 2024 11:45:00 Источник Nasdaq GlobeNewswire
-
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
24 июн 2024 01:00:00 Источник Nasdaq GlobeNewswire
-
05 июн 2024 01:00:00 Источник Nasdaq GlobeNewswire
-
VALNEVA - Declaration of shares and voting rights: May 31, 2024
04 июн 2024 12:00:00 Источник Nasdaq GlobeNewswire
-
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
04 июн 2024 11:35:00 Источник Nasdaq GlobeNewswire
-
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
03 июн 2024 11:35:00 Источник Nasdaq GlobeNewswire
-
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
31 май 2024 11:35:00 Источник Nasdaq GlobeNewswire
-
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
21 май 2024 01:00:00 Источник Nasdaq GlobeNewswire
-
13 май 2024 01:00:00 Источник Nasdaq GlobeNewswire
-
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
07 май 2024 01:00:00 Источник Nasdaq GlobeNewswire
-
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
06 май 2024 01:30:00 Источник Nasdaq GlobeNewswire
-
Declaration of voting rights - Valneva SE, March 2024
04 апр 2024 12:00:00 Источник Nasdaq GlobeNewswire
-
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
26 мар 2024 02:00:00 Источник Nasdaq GlobeNewswire
-
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
25 мар 2024 02:00:00 Источник Nasdaq GlobeNewswire